Brind.
  1. The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs.

ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.

3 reports, 2 independent Updated Aug 18
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
2
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.

Who's involved

What this event is mainly about
ImmunityBioFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. ImmunityBio met with the FDA division on August 5, 2025, to present data regarding its ANKTIVA drug used in an NCI cancer prevention trial.Sub-event
  2. Successful FDA approval of ANKTIVA drug, benefiting from the favorable environment created by tariffs and onshoring trends.1 source

Keep exploring

Part of

The FDA issued a Complete Response Letter for vatiquinone, while PTC Therapeutics leveraged partnerships with Novartis and Roche, alongside benefits for AI stocks due to Trump-era tariffs. All 2 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates We recently published 12 Best Healthcare Stocks to Buy Under $30. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best heal
  • Business WireImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients CULVER CITY, Calif., August 11, 2025--(BUSINESS
  • Insider MonkeyImmunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations ImmunityBio, Inc. (NASDAQ:IBRX) is one of the penny stocks that will skyrocket. On July 25, the company confirmed it is ey